Go to content

Publications

457 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Monitoring the vitamin D package measure

    The Minister of Health, Welfare and Sport (VWS) decided to discontinue the reimbursement of all vitamin D products containing ...

    Report | 01-12-2023

  2. Update advice on the lock procedure for the medicinal product atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

    The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to renegotiate the price of ...

    Report | 01-12-2023

  3. Final report – Case study phase ROR DGM

    The Dutch National Health Care Institute presents its vision on data availability in healthcare, based on 4 completed case ...

    Report | 30-11-2023

  4. GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

    The National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in ...

    Report | 22-11-2023

  5. Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

    The National Health Care Institute has assessed whether emicizumab (Hemlibra®) can be reimbursed from the basic health care ...

    Report | 16-11-2023

  6. Orphan drug arrangement givosiran (Givlaari®) for the treatment of acute hepatic porphyria

    Agreements have been made to promote appropriate use of givosiran (Givlaari®) as treatment of acute hepatic porphyria, a rare ...

    Publication | 24-10-2023

  7. Organisation chart 2023

    Organisation chart 2023

    Publication | 13-10-2023

  8. Conditional inclusion procedure for medicinal products

    This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

    Publication | 29-09-2023

  9. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

    The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

    Report | 21-09-2023

  10. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

    The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

    Report | 31-08-2023

Go to